Last reviewed · How we verify
NCT03912727
Alpha Lipoic Acid Against Cardiovascular Events in Patients With Haemodialysis
NA trial testing Alpha-Lipoic acid plus renal replacement therapy in Hemodialysis Complication in 36 participants. Completed in 1 September 2019.
30 August 2019
Quick facts
| Lead sponsor | Rehab Werida |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 36 |
| Start date | 11 April 2019 |
| Primary completion | 30 August 2019 |
| Estimated completion | 1 September 2019 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Alpha-Lipoic acid plus renal replacement therapy
- renal replacement therapy
Conditions studied
- Hemodialysis Complication — all drugs for Hemodialysis Complication →
Sponsor
Rehab Werida — full company profile →
Who can join
Adults 18 to 60, any sex, with Hemodialysis Complication. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluate the association between possible benefit effects of oral administration of alpha lipoic acid by patients with hemodialysis and the possible reduction in cardiovascular events (CVEs); using Advanced glycation end products (AGEs) as a measure to assess endothelium function which correlate with CVEs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03912727
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hemodialysis Complication
Currently open trials in the same condition.
- NCT07386691 — Comparing Effect of Intradialytic Aerobic Exercise Versus Incentive Spirometer on Fatigue and Sleep Quality Among Hemodi · NA · active not recruiting
- NCT07512895 — The Effect of Progressive Muscle Relaxation Exercises on Depression and Fatigue in Patients Receiving Hemodialysis Treat · NA · recruiting
- NCT07047547 — A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure · NA · recruiting
- NCT06452563 — Amino Acids Supplementation and Exercise Intervention in Hemodialysis Patients · Phase 4 · active not recruiting
- NCT06520631 — Response Of Arteriovenous Fistula Puncture-related Pain To Cryotherapy Application In Haemodialysis Patients · NA · recruiting
Other Rehab Werida trials
Trials by the same sponsor.
- NCT07379788 — ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling · recruiting
- NCT05813132 — BeEAM Versus CEM in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation · NA · completed
- NCT05459389 — Early Targeted Antibiotic Therapy in Patients With Sepsis · NA · completed
- NCT05459701 — Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD) · Phase 4 · completed
- NCT05291039 — Infliximab and Adalimumab in Inflammatory Bowel Disease Patients. · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03912727 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rehab Werida
- Last refreshed: 26 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03912727.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing